776 abstracts found.



Results filter

Over or under treatment? A systematic review and meta-analysis of factors determining change of management in active surveillance for localised prostate cancer

Year:

Session type:

Andrew Simpkin1, Kate Tilling1, Richard M Martin1,2, J Athene Lane1, Freddie C Hamdy3, Lars Holmberg4, David E Neal5, Chris Metcalfe1, Jenny L Donovan1
1School of Social and Community Medicine, University of Bristol, Bristol, UK, 2MRC Centre for Causal Analysis in Translational Epidemiology, University of Bristol, Bristol, UK, 3Nuffield Department of Surgical Sciences, University of Oxford, Oxford, Oxford, UK, 4Guy's Hospital, London, UK, 5Oncology Centre, Addenbrooke’s Hospital, Cambridge, UK

BACR Translational Research Award: Monitoring the cancer genome in plasma using circulating tumour DNA

Year:

Session type:

Nitzan Rosenfeld
Cancer Research UK Cambridge Institute and University of Cambridge, UK

Recognition of cancer warning signs and anticipated time to help-seeking in a population sample of adults in the UK

Year:

Session type:

Samantha L Quaife1, Lindsay JL Forbes2, Amanda J Ramirez2, Kate E Brain3, Conan Donnelly4, Alice E Simon5, Jane Wardle1
1Health Behaviour Research Centre, University College London, London, UK, 2Promoting Early Presentation Group, King's College London, London, UK, 3Cochrane Institute of Primary Care and Public Health, Cardiff University, Cardiff, UK, 4Centre for Public Health, Queen's University Belfast, Belfast, UK, 5City University, London, UK

Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomised in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither or both

Year:

Session type:

Nick James1, Sarah Pirrie1, Darren Barton1, Janet Brown2, Lucinda Billingham1, Stuart Collins1, Adam Daunton3, Alison Birtle4, Prabir Chakraborti5, Daniel Ford6, Syed Hussain7, Helen Jones1, Ann Pope1, Emilio Porfiri1, John Russell8, Andrew Stanley9, John Staffurth10, Duncan McLaren11, Chris Parker12, James Wylie13
1University of Birmingham, Birmingham, UK, 2Cancer Research UK Experimental Cancer Medicine Centres, Leeds, UK, 3West Midlands Strategic Health Authority, Birmingham, UK, 4Royal Preston Hospital, Preston, UK, 5Derby Royal Hospital, Derby, UK, 6Queen Elizabeth Hospital, Birmingham, UK, 7University of Liverpool, Liverpool, UK, 8Beatson West of Scotland Cancer Centre, Glasgow, UK, 9City Hospital, Birmingham, UK, 10Velindre Cancer Centre, Cardiff, UK, 11Edinburgh Cancer Centre, Edinburgh, UK, 12The Royal Marsden NHS Foundation Trust, Sutton, UK, 13The Christie Hospital NHS Foundation Trust, Manchester, UK

Age, smoking status and socioeconomic status as predictors of participation in the UK Lung Screen (UKLS) randomised controlled trial of low dose computed tomography (LDCT) for the early detection of lung cancer

Year:

Session type:

Fiona McRonald1, David Baldwin2, Anand Devaraj3, Kate Brain4, Tim Eisen5, John Holemans6, Martin Ledson6, Nicholas Screaton7, Robert C Rintoul7, Ghasem Yadegarfar1, Kate Lifford4, David Whynes2, Keith Kerr8, Richard Page6, Mahesh Parmar9, David Weller10, Paula Williamson11, David M Hansell11, Stephen W Duffy12, John K Field1
1The University of Liverpool, Liverpool, UK, 2The University of Nottingham, Nottingham, UK, 3St. George’s Hospital, London, UK, 4Cardiff University School of Medicine, Cardiff, UK, 5The University of Cambridge, Cambridge, UK, 6Liverpool Heart and Chest Hospital, Liverpool, UK, 7Papworth Hospital, Cambridge, UK, 8Aberdeen Royal Infirmary, Aberdeen, UK, 9Medical Research Council, London, UK, 10The University of Edinburgh, Edinburgh, UK, 11Royal Brompton Hospital, London, UK, 12Wolfson Institute, Barts & London University, London, UK

A polyphenol rich whole food supplement slows PSA progression in men with prostate cancer: A double-blind, placebo-controlled randomised trial – The NCRN Pomi-T study

Year:

Session type:

Robert Thomas1,2, Madeleine Williams1, Pat Bellamy2, Habinda Sharma1
1Bedford Hospital, Bedford, UK, 2Cranfield University, Bedford, UK, 3Addenbrooke's Hospital, Cambridge, UK

Mismatch between cancer symptom knowledge and symptom attribution in daily life: A population-based study

Year:

Session type:

Katriina Whitaker1, Una Macleod3, Alice Simon4, Suzanne Scott2, Jane Wardle1
1University College London, London, UK, 2King's College London, London, UK, 3Hull York Medical School, Hull, UK, 4City University, London, UK

The DietCompLyf study: A prospective cohort study of breast cancer survival and phytoestrogen consumption

Year:

Session type:

Ruth Swann1, Annie Perkins1, Louiza Velentzis2, Cristian Ciria3, Susan Dutton3, Angela Mulligan4, Jayne Woodside5, Marie Cantwell5, Anthony Leathem6, Claire Robertson1, Miriam Dwek1
1University of Westminster, London, UK, 2Cancer Council New South Wales, Sydney, Australia, 3University of Oxford, Oxford, UK, 4University of Cambridge, Cambridge, UK, 5Queen’s University Belfast, Belfast, UK, 6University College London, London, UK

HPV prevalence in screened population and types associated with Cervix disease in N. Ireland

Year:

Session type:

Lesley Anderson1, Michael O'Rorke2, Robbie Wilson3, Jackie Jamison4, Anna Gavin5
1Centre for Public Health, Queen's University Belfast, Belfast, UK, 2Centre for Public Health, Queen's University Belfast, Belfast, UK, 3Northern Health and Social Care Trust, Antrim Area Hospital, Antrim, UK, 4Northern Health and Social Care Trust, Antrim Area Hospital, Antrim, UK, 5N. Ireland Cancer Registry, Queen's University Belfast, Belfast, UK

Adjuvant Tamoxifen To offer more? (aTTom) – a randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years among 6953 women with ER positive or ER untested early breast cancer: Overall and subgroup findings.

Year:

Session type:

Daniel Rea1, Richard Gray2, Kelly Handley1, Sarah Bowden1, Helena Earl3, Christopher Poole4, Tom Bates7, John Dewar5, Zenon Rayter6, Martin Lee8
1University of Birmingham, Birmingham, UK, 2University of Oxford, Oxford, UK, 3University of Cambridge, Cambridge, UK, 4University of Warwick, Coventry, UK, 5University of Dundee, Dundee, UK, 6University of Bristol NHS Trust, Bristol, UK, 7William Harvey Hospital, Ashford, UK, 8NHS England, Coventry, UK

The effectiveness of a brief telephone-based intervention to improve fatigue in prostate cancer: A feasibility study

Year:

Session type:

Ben Langston1,2, Jo Armes1, Lucy Elliott2, Jocelyne James2, Emma Ream1
1King's College London, London, UK, 2Prostate Cancer UK, London, UK

PETROC / OV21 Randomised phase II/III Trial of PEritoneal Treatment for Ovarian Cancer: Initial results of the phase II study in preparation for extension to phase III. A collaborative trial of the NCRI, NCIC, GEICO, and SWOG  Gynaecological Cancer Study Groups.

Year:

Session type:

Chris Gallagher1, Alice Clark2, Mandy Feeney2, Lindsay James2, Charles Gourley4, Marcia Hall5, Geoff Hall6, Jonathan Ledermann3,2
1St Bartholomew's Hospital, London, UK, 2University College Hospital, London, UK, 3CRUK and UCL Cancer Trials Centre, London, UK, 4Western General Hospital, Edinburgh, UK, 5Mt Vernon Cancer Centre, Middlesex, UK, 6St Jame's Hospital, Leeds, UK

A randomised trial of 72 hour infusional bleomycin in BEP (cisplatin, etoposide  and bleomycin) versus conventional weekly bleomycin in patients with metastatic IGCCCG good prognosis disease

Year:

Session type:

Jonathan Shamash1, Robert Huddart2, Stephen Harland3, Johnathan Joffe4, Danish Mazhar5, Alison Birtle6, Jeff White7, Shah Jalal Sarker1, Peter Wilson1, Marita Marshall1, Sarah Vinnicombe8
1Barts Cancer Institute, London, UK, 2Royal Marsden Hospital, London, UK, 3University College London Cancer Institute, London, UK, 4Institute of Oncology, Leeds, UK, 5Addenbrooke's Hospital, Cambridge, UK, 6Royal Preston Hospital, Preston, UK, 7Beatson West of Scotland Cancer Centre, Glasgow, UK, 8Division of Cancer Research, Dundee, UK

Identification of plasma metabolite changes following phosphatidylinositol-3-kinase (PI3K) inhibition with GDC-0941, a potent and selective pan-Class I inhibitor of PI3K: preclinical discovery followed by clinical qualification in a Phase I clinical trial.

Year:

Session type:

Joo Ern Ang1,2, Rupinder Pandher1, Yasmin Asad1, Alan Henley1, Melanie Valenti1, Gary Box1, Alexis de haven Brandon1, Richard Baird1, Lori Friedman3, Mika Derynck3, Suzanne Eccles1, Stan Kaye1,2, Paul Workman1, Johann de Bono1,2, Florence Raynaud1,2
1Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, Sutton, Surrey, UK, 2Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK, 3Genentech Inc, South San Francisco, California, USA

Tumour- and treatment-related colostomy rates following 5Fluorouracil (5FU) and Mitomycin (MMC) or 5FU and Cisplatin (Cisp) chemoradiation (CRT) with or without maintenance chemotherapy in squamous cell carcinoma of the anus: Results of the randomised phase III trial ACT II

Year:

Session type:

Rob Glynne-Jones1, Latha Kadalayil2, Helen Meadows2, David Cunningham3, Les Samuel4, Ian Geh5, Charles Lowdell6, Roger James7, Sandy Beare2, Rubina Begum2, Jonathan Ledermann2, David Sebag-Montefiore8
1Mount Vernon Centre for Cancer Treatment, Northwood, UK, 2Cancer Research UK & University College London Cancer Trials Centre, London, UK, 3Royal Marsden Hospital, London, UK, 4Aberdeen Royal Infirmary, Aberdeen, UK, 5Queen Elizabeth Hospital, Birmingham, UK, 6Imperial College Healthcare NHS Trust, London, UK, 7Tonbridge, UK, 8St James’s Institute of Oncology, Leeds, UK

Modafinil for fatigue in lung cancer: multicentre, randomised, double-blinded, placebo-controlled trial: effect, dose response and patient satisfaction

Year:

Session type:

Bee Wee1,4, Susan Dutton1, Kate Fife2, Fiona Blackhall3, Ronja Bahadori4, Rose Wharton1, Mary O'Brien5, Paddy Stone6, Tim Benepal6, Anna Spathis2
1University of Oxford, Oxford, UK, 2Addenbrookes Hospital, Cambridge, UK, 3Christie Hospital, Manchester, UK, 4Oxford University Hospitals NHS Trust, Oxford, UK, 5Royal Marsden Hospital, London, UK, 6St George's Hospital, London, UK

Results from the UNBIASED study (UK – Netherlands – Belgium International SEDation study) : reported practices of physicians and nurses in three European countries

Year:

Session type:

Jane Seymour1, Luc Deliens2, Judith Rietjens2,3, Sigrid Sterckx4, Jayne Brown5, Agnes van der Heide3
1University of Nottingham, Nottingham, UK, 2Vrije Universiteit, Brussels, Belgium, 3Erasmus MC, Rotterdam, The Netherlands, 4Ghent University, Ghent, Belgium, 5De Montfort University, Leicester, UK

Obesity and the outcome of young breast cancer patients in the UK: The POSH study

Year:

Session type:

Ellen Copson1, Ramsey Cutress1, Bryony Eccles1, Clarice Wong1, Tom Maishman1, Sue Gerty1, Louise Dent1, Douglas Altman2, Lorraine Durcan1, Peter Simmonds1, the POSH steering group and D.M. Eccles1
1Cancer Sciences Academic Unit and Clinical Trials Unit, Faculty of Medicine, University of Southampton, Southampton, UK, 2Centre for Statistics in Medicine, Oxford, Oxford, UK

Reduction in interval cancer rates following the introduction of two-view mammography in the UK breast screening programme

Year:

Session type:

Amanda Dibden1, Judith Offman1, Dharmishta Parmar1, Jacquie Jenkins2, Jo Slater3, Kathie Binysh4, Joan McSorley5, Suzanne Scorfield6, Pam Cumming7, Xiao-Hui Liao8, Michael Ryan9, Diane Harker10, Guy Stevens11, Nicola Rogers12, Roger Blanks13, Sarah Sellars14, Julietta Patnick14, Stephen Duffy1
1Queen Mary, University of London, London, UK, 2East Midlands Quality Assurance Reference Centre, Nottingham, UK, 3East of England Quality Assurance Reference Centre, Cambridge, UK, 4London Quality Assurance Reference Centre, London, UK, 5Northern Ireland Quality Assurance Reference Centre, Belfast, UK, 6North East, Yorkshire and the Humber Quality Assurance Reference Centre, Newcastle Upon Tyne, UK, 7North West Quality Assurance Reference Centre, Oldham, UK, 8South Central Quality Assurance Reference Centre, Oxford, UK, 9South East Coast Quality Assurance Reference Centre, East Sussex, UK, 10South West Quality Assurance Reference Centre, Bristol, UK, 11Public Health Wales, Cardiff, UK, 12West Midlands Quality Assurance Reference Centre, Birmingham, UK, 13University of Oxford, Oxford, UK, 14NHS Cancer Screening Programmes, Sheffield, UK

NRP1 drives tip-cell selection downstream of Notch signaling by inhibiting ALK5 activation

Year:

Session type:

Irene Maria Aspalter1, Emma Gordon2, Anne Eichmann2, Holger Gerhardt1
1London Research Institute CRUK, London, UK, 2Yale School of Medicine, New Haven, USA

An all-Ireland population-based study of past and current physical and psychological side-effects following prostate cancer treatments

Year:

Session type:

Heather Kinnear1, Frances Drummond2, Linda Sharp2, Anna Gavin1Lesley Anderson1
1Queen's University Belfast, Belfast, UK, 2National Cancer Registry Ireland, Cork, Ireland

Clinical outcome following video-assisted thoracoscopic surgery (VATS) or thoracotomy in the surgical management of lung cancer: A multicentre UK analysis from 2001-2013

Year:

Session type:

Jason Sangha1, Felicity Evison2, Daniel Ray2, Paul Moss2
1University of Birmingham, Birmingham, UK, 2University of Birmingham, University Hospitals Birmingham NHS Foundation Trust and Birmingham CRUK Centre, Birmingham, UK

CUP pathway in North West London Hospital Trust (NWLHT): What lessons can we learn and how has the patient journey improved?

Year:

Session type:

Emma Kenney-Herbert1, Sheila Small2, Charles Daniels2, Charlotte Clare2
1Imperial College, London, UK, 2North West London Hospital Trust, London, UK

A metric for palliative radiotherapy – Pilot study

Year:

Session type:

Melissa Tan1, Matthew Williams1
1Imperial College Healthcare NHS Trust, London, UK

Streamlining in-patient oncology care: Squaring the circle

Year:

Session type:

Catherine Urch1, James Thomas1, Marjorie Jones1, Winsome Thomas1, Steve Nicholson1, Diane Dunn1, Gareth Gywnn1, Chris Harrison1, Matt Williams1, Melissa Tan1
1Charing Cross Hospital, London, UK

A unique set of pharma-academic clinical collaborations

Year:

Session type:

Val Baker1, Karina Meachin1, Helen Gillard1, Tim Henry1, Chiara Defendini1, Heather Laws1
1AstraZeneca, Alderley Park, UK

Creating combination treatment opportunities for patients and academia

Year:

Session type:

Lyndall McLellan1, Cathy McDowell1, Ian Walker1
1Drug Development Office, Cancer Research UK, London, UK

AZ Student Prize winner: MicroRNA-135b promotes cancer progression acting as a downstream effector of oncogenic pathways in colon cancer

Year:

Session type:

Nicola Valeri1, Chiara Braconi1, Pierluigi Gasparini2, Claudio Murgia3, Andrea Lampis1, Matteo Fassan7, Viola Paulus-Hock1, Jonathan Hart4, Sergei Grivennikov5, Francesca Lovat2, Giovanni Lanza6, Roberta Gafa'6, Gerard Nuovo2, Rachel Ridgway3, Wendy Frankel2, Joanna Groden2, Peter Vogt4, Owen Sansom3, Michael Karin5, Carlo Croce2
1Institute of Cancer Sciences, University of Glasgow, Glasgow, UK, 2The Ohio State University, Columbus, USA, 3Beatson Institute for Cancer Research, Glasgow, UK, 4The Scripps Research Institute, La Jolla, USA, 5University California at San Diego, San Diego, USA, 6University of Ferrara, Ferrara, Italy, 7ARC-NET Research Centre University of Verona, Verona, Italy

Evaluation of PIK3CA mutation as a predictor of benefit from NSAID therapy in colorectal cancer

Year:

Session type:

David Church1,2, Enric Domingo1, Oliver Sieber3, Rajarajan Ramamoorthy1,4, Brian Davidson4, David Kerr2, Rachel Midgley2, Ian Tomlinson1
1The Wellcome Trust Centre for Human Genetics, Oxford, UK, 2Oxford Cancer Centre, University of Oxford, Oxford, UK, 3Ludwig Institute for Cancer Research, Melbourne, Australia, 4University College London, London, UK

miR-21 down-regulates Junctional Adhesion Molecule-A (JAM-A) during colorectal cancer progression

Year:

Session type:

Andrea Lampis1, Claudio Murgia2, Viola Paulus-Hock1, Matteo Fassan3, Joanne Edwards1, Paul Horgan1, Owen Sansom2, Michael Karin4, Carlo Croce5, Chiara Braconi1, Nicola Valeri1
1Institute of Cancer Sciences, University of Glasgow, Glasgow, UK, 2The Beatson Institute for Cancer Research, Glasgow, UK, 3ARC-NET Research Centre, University of Verona, Verona, Italy, 4University of California, San Diego, USA, 5The Ohio State University, Columbus, USA

Deep analysis of signalling plasticity in a breast cancer kinase network during acquisition of resistance to PI3K and mTORC1/2 inhibitors

Year:

Session type:

Edmund Wilkes1,2, Pedro Cutillas1,2
1Barts Cancer Institute, Queen Mary University of London, School of Medicine and dentistry, London, UK, 2MRC Clinical Sciences Centre, London, UK

Pan-genomic analysis of hypoxic breast cancer reveals lncRNAs associated with clinicopathological features

Year:

Session type:

Hani Choudhry1,2, Johannes Schödel3, Carme Camps2, Spyros Oikonomopoulos2, Peter Ratcliffe3, Adrian Harris4, Ioannis Ragoussis2, David Mole3
1Biochemistry Department, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia, 2The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK, 3Henry Wellcome Building for Molecular Physiology, University of Oxford, Oxford, UK, 4Department of Oncology, John Radcliffe Hospital, University of Oxford, Oxford, UK

Antiproliferative and apoptotic answer of amifostine against gamma radiation on HeLa cell culture

Year:

Session type:

Gul Ozcan Arican1, Ozlem Dagdeviren2, Ugur Serbes2, Idil Cetin1,2
1Istanbul University, Science Faculty, Radiobiology Section, Istanbul, Turkey, 2Istanbul University, Institute of Science, Istanbul, Turkey

Volatile biomarkers discriminate between bronchial epithelial cells with distinct mutations

Year:

Session type:

Michael Davies1, Orna Barash2, Raneen Jeries2, Nir Peled3, Maya Ilouze3, Russell Hyde1, Michael Marcus1, Hossam Haick2, John Field1
1University of Liverpool, Liverpool, UK, 2Technion - Israel Institute of Technology, Haifa, Israel, 3Tel Aviv University, Tel Aviv, Israel

Comparison of breast cancer incidence trends by site in the US between 1973-2009

Year:

Session type:

Chloe Bright1, Richard Feltbower1
1University of Leeds, Leeds, UK

CCP Score: A novel genetic test for prostate cancer

Year:

Session type:

Dan Berney1, Michael Brawer2, Matthew Cooperberg3, Gregory Swanson4, Stephen Freedland5, Julia Reid2, Gabrielle Fisher1, Gerry Lanchbury2, Alexander Gutin2, Steven Stone2, Peter Carroll3, Jack Cuzick1
1Queen Mary University of London, London, UK, 2Myriad Genetic Laboratories, Salt Lake City, USA, 3University of California, San Francisco, USA, 4University of Texas Health Science Center at San Antonio, San Antonio, USA, 5Duke University Medical Center and Durham VA Medical Center, Durham, USA

Development of an integrated online toxicity reporting and management system for oncology: eRAPID(electronic patient self-Reporting of Adverse-events: Patient Information and aDvice) 

Year:

Session type:

Patricia Holch1, Leon Bamforth1, Lorraine Warrington1, Ada Keding2, Lucy Ziegler3, Kate Absolom1, Ceri Hector1, Lucy Kenyan1, Clare Harley4, Owen Johnson5, Geoff Hall6, Galina Velikova1
1University of Leeds, Psychosocial Oncology Clinical Practice Research Group, St James's Institute of Oncology, Bexley Wing,, Leeds, UK, (YTU) University of York, York Trials Unit, 3University of Leeds, Institute of Health Sciences,, Leeds, UK, 4University of Leeds, School of Health Care, Baines Wing, Leeds, UK, 5University of Leeds, Yorkshire Centre for Health Informatics, Leeds, UK, 6Leeds Teaching Hospitals NHS Trust, St James's University Hospital, Leeds, UK

BACR AZ Frank Rose Award: The signalling networks regulating cell shape

Year:

Session type:

Chris Bakal
The Institute of Cancer Research, London UK

Quantifying research participants in follow up across the NCRN

Year:

Session type:

Rachel Bolton1
1NIHR Lancashire and South Cumbria Cancer Research Network, NCRN, UK

The Hippo pathway polarises the actin cytoskeleton during collective migration of Drosophila border cells

Year:

Session type:

Ichha Khanal1, Eliana Lucas1, Pedro Gaspar1, Georgina Fletcher1, Cedric Polesello1, Nicolas Tapon1, Barry Thompson1
1Cancer Research UK London Research Institute, London, UK

Adjustment for patient case-mix makes little difference to English hospital performance ranks for cancer patient experience: Evidence from English Cancer Patient Experience Surveys

Year:

Session type:

Georgios Lyratzopoulos11, Catherine Saunders1, Gary Abel1
1University of Cambridge, Cambridge, UK

The role of palliative radiotherapy for haemostasis in irresectable gastric cancer

Year:

Session type:

Cheng Lee Chaw1, CS Chaw2, Paddy Niblock1, Douglas Adamson1
1Oncology Department, Ninewells Hospital and Medical School, Dundee, UK, 2Faculty of Applied Science, Department of Pharmacy, University of Sunderland, Sunderland, UK

Neoadjuvant chemotherapy for triple negative breast cancer: The role of carboplatin

Year:

Session type:

Usha Alluri1, Tania Tillett1, Jeremy Braybrooke1, Charles Comins1, Chris Price1
1Bristol Haematology & Oncology Centre, Bristol, UK

Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial

Year:

Session type:

JA Ledermann1, T Perren2, FA Raja1,3, AC Embleton3, GJS Rustin4, G Jayson5, SB Kaye6, A Swart7,3, M Vaughan8, H Hirte9
1Cancer Research UK & UCL Cancer Trials Centre, London, UK, 2St. James University Hospital, Leeds, UK, 3Medical Research Council Clinical Trials Unit at UCL, London, UK, 4Mount Vernon Hospital, Northwood, UK, 5Christie Hospital, Manchester, UK, 6Royal Marsden Hospitals, London, UK, 7University of East Anglia, Norwich, UK, 8Christchuch Hospital, Christchurch, New Zealand, 9Hamilton Regional Cancer Centre, Ontario, Canada

Alliances that bring opportunities for patients, academia and industry 

Year:

Session type:

Clare Shaw1, Matt Cooper1, Rob Coleman1, Poulam Patel1, Matt Seymour1
1(NCRN) National Institute for Health Research Cancer Research Network

Clinical experience with aflibercept in metastatic colorectal cancer (mCRC): A single institution experience

Year:

Session type:

Betsan Mai Thomas1, Seema Arif1, Alison Brewster1, Kein Yim1, Hilary Williams1, Paul Shaw1,2, Robert Jones1,2, Richard Adams2,1
1Velindre Cancer Centre, Cardiff, UK, 2Cardiff University, Cardiff, UK

Nanoemulsion based concomitant delivery of curcumin and etoposide: Impact on cross talk between prostate cancer cells and osteoblast

Year:

Session type:

Prabhat Ranjan Mishra1, Prashant Shukla1, Vineet Mathur1, Amit Kumar1, Vikram Khedgikar1, B Venkatesh Teja1, Dharmendra Chaudhary1, Priyanka Kushwaha1, Ritu Trivedi1, Himangsu K Bora1, Rituraj Konwar1
1CSIR-Central Drug Research Institute, Lucknow, India

Treatment of disseminated melanoma with 211At-MTB

Year:

Session type:

Eva Link1
1University of London, London, UK

Tobacco related behaviour and attitudes and cancer/health risk among the adult population residing in a resettlement colony of New Delhi, India

Year:

Session type:

Suman Bhasker1, Vikas Bajpai2, Vinay Kumar3
1All India Institute of Medical Sciences, New Delhi, India, 2Jawahar Lal Nehru University, New Delhi, India, 3Kidwai Memorial Institute of Oncology, Bangalore, India

Age inequalities in the surgical management of colorectal cancer across England: 1998 to 2008

Year:

Session type:

Rebecca Birch1, Amy Downing1, Katie Harris1, James Thomas2, Phil Quirke1, Paul Finan3,1, Eva Morris1
1University of Leeds, Leeds, UK, 2National Cancer Intelligence Network, London, UK, 3Leeds Teaching Hospitals NHS Trust, Leeds, UK